Skip to Main Content
Table 10—

Reduction in 10-year risk of major CVD end points (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

Study (ref.)CVD preventionStatin dose and comparatorRisk reduction (%)Relative risk reduction (%)Absolute risk reduction (%)LDL cholesterol reduction
4S-DM (186) 2° Simvastatin 20–40 mg vs. placebo 85.7 to 43.2 50 42.5 186 to 119 mg/dl (36%) 
ASPEN 2° (191) 2° Atorvastatin 10 mg vs. placebo 39.5 to 24.5 34 12.7 112 to 79 mg/dl (29%) 
HPS-DM (187) 2° Simvastatin 40 mg vs. placebo 43.8 to 36.3 17 7.5 123 to 84 mg/dl (31%) 
CARE-DM (188) 2° Pravastatin 40 mg vs. placebo 40.8 to 35.4 13 5.4 136 to 99 mg/dl (27%) 
TNT-DM (189) 2° Atorvastatin 80 mg vs. 10 mg 26.3 to 21.6 18 4.7 99 to 77 mg/dl (22%) 
HPS-DM (187) 1° Simvastatin 40 mg vs. placebo 17.5 to 11.5 34 6.0 124 to 86 mg/dl (31%) 
CARDS (209) 1° Atorvastatin 10 mg vs. placebo 11.5 to 7.5 35 118 to 71 mg/dl (40%) 
ASPEN (191) 1° Atorvastatin 10 mg vs. placebo 9.8 to 7.9 19 1.9 114 to 80 mg/dl (30%) 
ASCOT-DM (190) 1° Atorvastatin 10 mg vs. placebo 11.1 to 10.2 0.9 125 to 82 mg/dl (34%) 
Study (ref.)CVD preventionStatin dose and comparatorRisk reduction (%)Relative risk reduction (%)Absolute risk reduction (%)LDL cholesterol reduction
4S-DM (186) 2° Simvastatin 20–40 mg vs. placebo 85.7 to 43.2 50 42.5 186 to 119 mg/dl (36%) 
ASPEN 2° (191) 2° Atorvastatin 10 mg vs. placebo 39.5 to 24.5 34 12.7 112 to 79 mg/dl (29%) 
HPS-DM (187) 2° Simvastatin 40 mg vs. placebo 43.8 to 36.3 17 7.5 123 to 84 mg/dl (31%) 
CARE-DM (188) 2° Pravastatin 40 mg vs. placebo 40.8 to 35.4 13 5.4 136 to 99 mg/dl (27%) 
TNT-DM (189) 2° Atorvastatin 80 mg vs. 10 mg 26.3 to 21.6 18 4.7 99 to 77 mg/dl (22%) 
HPS-DM (187) 1° Simvastatin 40 mg vs. placebo 17.5 to 11.5 34 6.0 124 to 86 mg/dl (31%) 
CARDS (209) 1° Atorvastatin 10 mg vs. placebo 11.5 to 7.5 35 118 to 71 mg/dl (40%) 
ASPEN (191) 1° Atorvastatin 10 mg vs. placebo 9.8 to 7.9 19 1.9 114 to 80 mg/dl (30%) 
ASCOT-DM (190) 1° Atorvastatin 10 mg vs. placebo 11.1 to 10.2 0.9 125 to 82 mg/dl (34%) 

Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation, results of the statin on 10-year risk of major CVD end points (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, Pharm.D., Oregon Health & Science University, 2007.

Close Modal

or Create an Account

Close Modal
Close Modal